Last reviewed · How we verify

Docetaxel;oxaliplatin;s1

Chinese Academy of Medical Sciences · Phase 3 active Small molecule

Docetaxel;oxaliplatin;s1 is a Chemotherapy combination (taxane + platinum + fluoropyrimidine) Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Advanced or metastatic gastric cancer, Esophageal cancer.

This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously.

This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously. Used for Advanced or metastatic gastric cancer, Esophageal cancer.

At a glance

Generic nameDocetaxel;oxaliplatin;s1
SponsorChinese Academy of Medical Sciences
Drug classChemotherapy combination (taxane + platinum + fluoropyrimidine)
TargetMultiple: microtubules (docetaxel), DNA (oxaliplatin), thymidylate synthase (S-1)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Docetaxel stabilizes microtubules to prevent cell division, oxaliplatin creates DNA crosslinks to prevent replication, and S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase and incorporates into DNA/RNA. The triple combination exploits synergistic cytotoxic effects across different cell-cycle phases and molecular targets, commonly used in gastric and esophageal cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Docetaxel;oxaliplatin;s1

What is Docetaxel;oxaliplatin;s1?

Docetaxel;oxaliplatin;s1 is a Chemotherapy combination (taxane + platinum + fluoropyrimidine) drug developed by Chinese Academy of Medical Sciences, indicated for Advanced or metastatic gastric cancer, Esophageal cancer.

How does Docetaxel;oxaliplatin;s1 work?

This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously.

What is Docetaxel;oxaliplatin;s1 used for?

Docetaxel;oxaliplatin;s1 is indicated for Advanced or metastatic gastric cancer, Esophageal cancer.

Who makes Docetaxel;oxaliplatin;s1?

Docetaxel;oxaliplatin;s1 is developed by Chinese Academy of Medical Sciences (see full Chinese Academy of Medical Sciences pipeline at /company/chinese-academy-of-medical-sciences).

What drug class is Docetaxel;oxaliplatin;s1 in?

Docetaxel;oxaliplatin;s1 belongs to the Chemotherapy combination (taxane + platinum + fluoropyrimidine) class. See all Chemotherapy combination (taxane + platinum + fluoropyrimidine) drugs at /class/chemotherapy-combination-taxane-platinum-fluoropyrimidine.

What development phase is Docetaxel;oxaliplatin;s1 in?

Docetaxel;oxaliplatin;s1 is in Phase 3.

What are the side effects of Docetaxel;oxaliplatin;s1?

Common side effects of Docetaxel;oxaliplatin;s1 include Neutropenia, Anemia, Thrombocytopenia, Nausea/vomiting, Diarrhea, Peripheral neuropathy.

What does Docetaxel;oxaliplatin;s1 target?

Docetaxel;oxaliplatin;s1 targets Multiple: microtubules (docetaxel), DNA (oxaliplatin), thymidylate synthase (S-1) and is a Chemotherapy combination (taxane + platinum + fluoropyrimidine).

Related